Mycophenolate Sodium (Myfortic®) in the Treatment of Corticosteroid-refractory Autoimmune Uveitis:Pilot Study
NCT ID: NCT01261169
Last Updated: 2010-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
40 participants
OBSERVATIONAL
2009-01-31
2011-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There will be no other stratification of patients. After the screening, patients will be treated with Myfortic® for 6 months. Patients will be seen at month 1, 3, and 6. Thereafter patients will be followed up at month 12. Efficacy and safety assessments will be performed at each visit.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myfortic
Myfortic
Myfortic in uveitis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myfortic
Myfortic in uveitis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Ocular sarcoidosis: a granulomatous uveitis with posterior inflammation in a patient in which sarcoidosis has been established by means of a biopsy, cytology, or a positive scan.
2. Intermediate uveitis: patients with clinical features as defined by the IUSG23. However, it is important that the patient has no evidence of a systemic infection such as Lyme Borreliosis and that there is no history of neurological symptoms likely to be associated with multiple sclerosis. All patients with intermediate uveitis should have a negative MRI with gadolinium contrast, prior to being enrolled.
3. Behçet's syndrome: the international classification criteria of the International Society for Behçet's Disease (ISBD) will be used to define these patients.
4. Idiopathic Retinal Vasculitis where systemic or infectious causes have been eliminated. In particular patients will not have evidence of Wegener's granulomatosis, SLE, PAN, polymyositis, dermatomyositis or other systemic vasculitic disorders. Patients must also lack evidence for a systemic infection, and have been adequately screened. For the purpose of this study, Eale's disease will be excluded from the idiopathic retinal vasculitis group. However, both non-occlusive and occlusive types of retinal vasculitis can be included in the study.
5. Vogt-Koyanagi-Harada disease (VKH) as defined according to the international Workgroup definition of VKH.
6. Sympathetic ophthalmia: a granulomatous uveitis involving the choroid and retina, characterized by multiple white-yellow lesions often in the periphery, which can coalesce particularly in the circumpapillary region. It is associated with trauma or multiple prior surgeries.
7. Idiopathic panuveitis: all non-infectious panuveititides that can not be related to the diseases mentioned above.
8. Corticosteroid-refractory uveitis patient is defined as the patient who receive steroid treatment and cannot lower the dosage of steroid to less than 10mg per day in 3 months due to the clinical condition.
2. Disease that is 5 years or less in duration, with a significant flare in the past 24 months requiring intensification of anti-inflammatory therapy (predsinolone). A significant flare is defined as a drop of 2 lines of vision on an ETDRS chart or equivalent, or increase in vitreous flare by 2 grades.
3. Visual acuity of 0.1 or better in at least one eye.
4. Men and women of childbearing potential must use adequate birth control measures (e.g., abstinence, oral contraceptives, intrauterine device, barrier method with spermicidal cream, or surgical sterilization) for the duration of the study and should continue such precautions for 6 weeks after receiving the last administration.
5. The screening laboratory test results must meet the following criteria:
1. Hemoglobin ≥ 10.5 g/dL
2. WBC ≥ 3.0 x 103/μL
3. Neutrophils ≥ 1.5 x 103/μL
4. Platelets ≥ 1 x 103/μL
5. SGOT (AST) and alkaline phosphatase levels must be within 3 times the upper limit of normal range for the laboratory conducting the test (3xULN).
6. Creatinine clearance \> 25 ml/min
6. Must have a normal chest radiograph within 3 months prior to first therapy with no evidence of malignancy, infection or TB.
7. Patient must be able to adhere to the study visit schedule and other protocol requirements.
8. The patient must be capable of giving informed consent and the consent must be obtained prior to any screening procedures.
Exclusion Criteria
2. Patients requiring ocular surgery within the initial 3 months of treatment, or who have had surgery in the prior 3 months.
3. Women who are pregnant, nursing, or planning pregnancy within 6 months after screening (i.e., approximately 6 weeks following last treatment).
4. Use of any investigational drug within 1 month prior to screening or within 5 half-lives of the investigational agent, whichever is longer.
5. Recent history of systemic immunosuppressive therapy, other than steroids for ocular disease within 2 months.
6. Creatinine clearance of \< 25ml/min or serum creatinine level higher than 1.5 mg/dl
7. Patients with known hypersensitivity to prednisone, Myfortic® or drugs with similar chemical structures.
8. Patients with any clinically significant infection.
9. Documented HIV infection.
10. Patients with active TB or evidence of latent TB.
11. Patients with positive Lues serology and or significant Lues infection.
12. Patients with opportunistic infections, including but not limited to evidence of active cytomegalovirus, active Pneumocystis carinii, Aspergillosis, Histoplasmosis or atypical mycobacterium infection, etc, within the previous 6 months.
13. Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic,hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, or cerebral disease.
14. Presence of a transplanted organ (with the exception of a corneal transplant 3 months prior to screening).
15. Malignancy within the past 5 years (except for treated squamous or basal cell carcinoma of the skin without evidence of recurrence).
16. History of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (such as nodes in the posterior triangle of the neck, infra-clavicular, epitrochlear, or periaortic areas), or splenomegaly.
17. Known recent substance abuse (drugs or alcohol).
18. Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling during the study period.
19. Recent live vaccinations
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novartis
INDUSTRY
Genovate Biotechnology Co., Ltd.,
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Yih-Shiou Hwang
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hwang Yih Shiou, MD
Role: PRINCIPAL_INVESTIGATOR
CGMH
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CGMH
Taoyuan, Taiwan, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Hwang Yih Shiou, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CERL080ATW06T
Identifier Type: -
Identifier Source: org_study_id